RxDoctor Payments Data

Stephen Turner, MD

Cardiovascular Disease · Corpus Christi, TXNPI 1508866252

Payments from drug & device makers

$3,365in general payments, 2019–2025

Across 144 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Pfizer$428
  • Boston Scientific$327
  • Preventice Services, LLC$266
  • Johnson & Johnson$227
  • Abiomed$163
  • plus $742 from 15 others

What the payments were for

  • Food & beverage$3,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,365 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$292,179
Medicare patients
876
Services billed
3,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban472$443,596
XareltoRivaroxaban51$52,361
Repatha SureclickEvolocumab49$29,167
Praluent PenAlirocumab13$8,785
Clonidine24$4,483
Metoprolol Succinate373$4,423
Diltiazem 24hr Er (Cd)Diltiazem Hcl130$3,968
Digoxin133$3,493
Ranolazine ErRanolazine30$3,140
Amlodipine Besylate440$2,801
Atorvastatin Calcium321$2,579
Labetalol Hcl118$2,139
Potassium Chloride113$2,106
Nifedipine ErNifedipine44$2,100
ClopidogrelClopidogrel Bisulfate217$2,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$428$443,596472 claims
Johnson & JohnsonXarelto$227$52,36151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →